Table 7.
References | Study design | Subjects (n) | Age, years (mean ± SD) | Disease/symptom | Kampo formulation | Comparator | Outcome |
---|---|---|---|---|---|---|---|
Jo et al. (146) | Propensity score analysis | 2385 | 82.1 ± 4.8 82.1 ± 4.8 | Chronic obstructive pulmonary disease exacerbation | DKT | No DKT | DKT users had a significantly lower risk of re-hospitalization or death after discharge. Subgroup analysis of long-acting muscarinic receptor antagonists users showed a significant difference in re-hospitalization or death, while subgroup analysis of long-acting muscarinic receptor antagonists non-users showed no significant difference. |
Yasunaga (147) | Propensity score analysis | 7758 | 76.2 (10.7) 76.2 (10.7) | Chronic subdural hematoma | GRS | No GRS | GRS use was significantly associated with a lower reoperation rate compared with non-use. |
Yasunaga et al. (148) | Propensity score analysis | 288 | 68.4 ± 10.1 67.9 ± 9.1 | Postoperative adhesive small bowel obstruction requiring long-tube decompression | DKT | No DKT | Patients who received DKT showed significant shorter duration of long-tube decompression (LTD), shorter duration between long-tube insertion and discharge, and lower hospital charges compared with patients without DKT. It suggested that DKT is effective for reducing the duration of LTD and saving costs. |
DKT, daikenchuto; GRS, goreisan; SD, standard deviation.